钙通道阻滞剂是治疗心血管疾病最常用的药物之一。它们的长期使用有几种已知的副作用，但其他可能的不良反应尚未被证实。本研究旨在评估钙通道阻滞剂暴露与二次原发恶性肿瘤发生率之间的关联。我们建立了一个1401名结肠直肠癌患者的队列，诊断时间从2003年1月到2016年12月，在2020年12月进行了随访。从医院信息系统数据库获取了肿瘤特征和基本临床数据，包括药物信息。在301名患者(21.5%)中发现了二次恶性肿瘤，其中使用钙通道阻滞剂的患者的发生率为27.8%，而非使用者的发生率仅为19.9%。它们的使用与膀胱癌的发生率增加特别相关。对第二次恶性肿瘤患者的亚分析显示，在非使用者中右侧结肠癌的比例高于直肠癌。生存分析显示，早期结肠直肠癌患者若无钙通道阻滞剂治疗或二次原发恶性肿瘤史，则预后显著更好。© 2023年作者。

Calcium channel blockers are among the most commonly used agents in the treatment of cardiovascular diseases. There are several known side-effects associated with their long-term use, whereas other potential adverse effects are yet to be proven. This study aims to evaluate the association between calcium channel blockers exposure and the incidence of second primary malignancy. We established a cohort of 1401 patients with colorectal cancer diagnosed in our institution between January 2003 and December 2016. Patients were followed-up until December 2020. The tumor characteristics and basic clinical data including medication information were obtained from the hospital information system database. Second malignancy was detected in 301 patients (21.5%), and occurred in 27.8% of patients who used calcium channel blockers compared to only 19.9% among non-users. Their use was associated with an increased incidence of bladder cancer in particular. Subanalysis of patients with second malignancy displayed a higher proportion of right-sided colon cancer compared to rectal carcinoma in non-users. Survival analysis revealed significantly better outcomes in early-stage colorectal cancer patients without a history of calcium channel blockers treatment or second primary malignancy.© 2023. The Author(s).